Two Sigma Advisers LP Takes Position in INmune Bio, Inc. (NASDAQ:INMB)

Two Sigma Advisers LP bought a new position in shares of INmune Bio, Inc. (NASDAQ:INMB) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 12,700 shares of the company’s stock, valued at approximately $59,000. Two Sigma Advisers LP owned about 0.06% of INmune Bio at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of INMB. Wells Fargo & Company MN boosted its stake in INmune Bio by 51.0% during the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company’s stock worth $30,000 after purchasing an additional 2,155 shares during the period. Beacon Pointe Advisors LLC purchased a new stake in shares of INmune Bio in the fourth quarter valued at about $48,000. JPMorgan Chase & Co. boosted its stake in shares of INmune Bio by 93.0% during the fourth quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company’s stock worth $53,000 after buying an additional 5,461 shares during the period. Mariner LLC acquired a new stake in shares of INmune Bio during the fourth quarter worth about $65,000. Finally, Financial Advocates Investment Management grew its holdings in shares of INmune Bio by 14.8% during the fourth quarter. Financial Advocates Investment Management now owns 15,500 shares of the company’s stock worth $72,000 after buying an additional 2,000 shares during the last quarter. 12.72% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on INMB. Scotiabank increased their price objective on INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, February 11th. Maxim Group increased their price target on INmune Bio from $22.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $22.80.

INmune Bio Stock Up 3.7%

Shares of NASDAQ:INMB opened at $7.62 on Monday. INmune Bio, Inc. has a 52 week low of $4.32 and a 52 week high of $10.50. The company has a 50-day moving average price of $7.49 and a 200 day moving average price of $7.14. The company has a market cap of $175.14 million, a P/E ratio of -3.50 and a beta of 1.55.

INmune Bio (NASDAQ:INMB) last issued its earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.43). The business had revenue of $0.05 million for the quarter. Analysts expect that INmune Bio, Inc. will post -2.24 EPS for the current year.

INmune Bio Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.